Request Demo

Last update 08 May 2025

Arginine Aspirin

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

COXs

Action

inhibitors

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

FeverPainRheumatoid Arthritis

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC15H22N4O6

InChIKeyFXXXGQLMXDIPQA-VWMHFEHESA-N

CAS Registry37466-21-0

100 Clinical Results associated with Arginine Aspirin

100 Translational Medicine associated with Arginine Aspirin

100 Patents (Medical) associated with Arginine Aspirin

Literatures (Medical) associated with Arginine Aspirin

01 Jan 1989·Yao xue xue bao = Acta pharmaceutica Sinica

[Effects of arginine aspirin on changes in effective refractory period and ventricular fibrillation threshold of ischemic myocardium in rabbit].

Article

Author: Zhou, Y Y ; Zhao, R R ; Zang, Y M ; Zhu, M Z ; Wu, B W ; Zhao, Z Q

The effects of arginine aspirin (AAs) on the effective refractory period (ERP) and ventricular fibrillation threshold (VFT) of ischemic ventricular muscle were observed in 24 anesthetized open-chest rabbits. that the platelet aggregation rate was shown to be increased by 11 +/- 5%, and VFT decreased by 24 +/- 3 mA at 50 min after coronary occlusion. Compared with values at 10 min postocclusion, ERP of ventricular muscle in border ischemic zone (BIZ) and central ischemic zone (CIZ) was shortened by 20 +/- 10% and prolonged by 35 +/- 22 ms, respectively, and dispersions of ERP between CIZ and BIZ were increased by 52 +/- 17 ms, compared with control values, (p less than 0.01). By giving an intravenous injection of AAs at 0.5 h before coronary occlusion, changes in parameters as mentioned above were obviously relieved as compared with the same parameters in the group of simple coronary occlusion at 50 min postocclusion, (p less than 0.01). These results suggest that AAs may inhibit platelet aggregation, reduce dispersions of ERP and elevate VFT after coronary occlusion.

Zhongguo Yaoxue Zazhi (Beijing, China)

Effects of arginine aspirin on diastolic functional changes in dogs with myocardial ischemia

Author: Zhao, Rongrui ; Liu, Bing ; Zang, Yimin ; Zhao, Zhiqing ; Zhu, Miaozhang

In dogs with exptl. myocardial ischemia, platelet aggregation was increased and left ventricular diastolic functions were changed after occlusion of the coronary artery.I.v. infusion of arginine aspirin inhibited platelet aggregation and changes in left ventricular diastolic functions induced by coronary occlusion.Thus, arginine aspirin may be beneficial in treatment of acute myocardial ischemia.

Acta Pharmaceutica Turcica

Preparation of aspirin - arginine salt

Author: Guven, Kasim C. ; Gonullu, Umit

Aspirin arginine salt was prepared from aspirin in MeOH-ether solution and arginine in EtOH-H₂O solution

100 Deals associated with Arginine Aspirin

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Fever	China	-	-
Pain	China	-	-
Rheumatoid Arthritis	China	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISC2018	Not Applicable	Intracranial Arteriovenous Malformations	11,066	Long-term aspirin use	(ilrbjjnlfu) = llyifxiieh iwmpbhxnov (ksuuixzfsc ) View more	-	22 Jan 2018
				Long-term anticoagulant use	(ilrbjjnlfu) = ijpjqpshjz iwmpbhxnov (ksuuixzfsc ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Arginine Aspirin

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation